Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2.

Nerurkar PV, Lee YK, Linden EH, Lim S, Pearson L, Frank J, Nerurkar VR.

Br J Pharmacol. 2006 Aug;148(8):1156-64. Epub 2006 Jul 3.


Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells.

Nerurkar PV, Pearson L, Efird JT, Adeli K, Theriault AG, Nerurkar VR.

J Nutr. 2005 Apr;135(4):702-6.


Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions.

Nerurkar PV, Lee YK, Motosue M, Adeli K, Nerurkar VR.

Br J Nutr. 2008 Oct;100(4):751-9. doi: 10.1017/S0007114508937430. Epub 2008 Mar 5.


Cotranslational inhibition of apoB-100 synthesis by cyclosporin A in the human hepatoma cell line HepG2.

Kaptein A, de Wit EC, Princen HM.

Arterioscler Thromb. 1994 May;14(5):780-9.


Inhibition of apolipoprotein B and triglyceride secretion in human hepatoma cells (HepG2).

Haghpassand M, Wilder D, Moberly JB.

J Lipid Res. 1996 Jul;37(7):1468-80.


Effects of dietary fats and cholesterol on liver lipid content and hepatic apolipoprotein A-I, B, and E and LDL receptor mRNA levels in cebus monkeys.

Hennessy LK, Osada J, Ordovas JM, Nicolosi RJ, Stucchi AF, Brousseau ME, Schaefer EJ.

J Lipid Res. 1992 Mar;33(3):351-60.


Demonstration of biphasic effects of docosahexaenoic acid on apolipoprotein B secretion in HepG2 cells.

Wu X, Shang A, Jiang H, Ginsberg HN.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3347-55.


Isolation and characterization of lipoproteins produced by human hepatoma-derived cell lines other than HepG2.

Forte TM, McCall MR, Knowles BB, Shore VG.

J Lipid Res. 1989 Jun;30(6):817-29.


Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes.

Nerurkar PV, Lee YK, Nerurkar VR.

BMC Complement Altern Med. 2010 Jun 29;10:34. doi: 10.1186/1472-6882-10-34.


Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipoproteins in hepatic cells.

Jamil H, Chu CH, Dickson JK Jr, Chen Y, Yan M, Biller SA, Gregg RE, Wetterau JR, Gordon DA.

J Lipid Res. 1998 Jul;39(7):1448-54.


Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.

Foulkes AS, Wohl DA, Frank I, Puleo E, Restine S, Wolfe ML, Dube MP, Tebas P, Reilly MP.

PLoS Med. 2006 Mar;3(3):e52.


Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1alpha on the expression of apolipoprotein M in HepG2 cells.

Xu N, Zhang XY, Dong X, Ekström U, Ye Q, Nilsson-Ehle P.

Biochem Biophys Res Commun. 2002 Apr 12;292(4):944-50.


The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice.

Riddle TM, Schildmeyer NM, Phan C, Fichtenbaum CJ, Hui DY.

J Lipid Res. 2002 Sep;43(9):1458-63.


The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III.

Kang SK, Chung TW, Lee JY, Lee YC, Morton RE, Kim CH.

J Biol Chem. 2004 Jul 2;279(27):28106-12. Epub 2004 Apr 29.


ApoA-IV modulates the secretory trafficking of apoB and the size of triglyceride-rich lipoproteins.

Weinberg RB, Gallagher JW, Fabritius MA, Shelness GS.

J Lipid Res. 2012 Apr;53(4):736-43. doi: 10.1194/jlr.M019992. Epub 2012 Jan 18.


Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions.

Sundaram M, Zhong S, Bou Khalil M, Links PH, Zhao Y, Iqbal J, Hussain MM, Parks RJ, Wang Y, Yao Z.

J Lipid Res. 2010 Jan;51(1):150-61. doi: 10.1194/M900346-JLR200.

Supplemental Content

Support Center